Homocysteine & Heart Disease: 7 Mechanisms Linking Elevated Levels to Cardiac Risk

Homocysteine as a Cardiovascular Risk Factor

Elevated plasma homocysteine (>15 µmol/L) independently predicts coronary, cerebral, and peripheral vascular events.

Pathogenic Mechanisms

  1. Endothelial injury: Reduces NO bioavailability, increases ADMA, promotes apoptosis.
  2. Pro-thrombotic state: ↑Tissue factor, ↓thrombomodulin, ↓protein C activation, ↑platelet adhesion, ↑Factor V/VII.
  3. Oxidative stress: Auto-oxidation generates H₂O₂, superoxide → LDL oxidation, foam cell formation.
  4. VSMC proliferation: Stimulates smooth muscle growth → intimal thickening, plaque progression.
  5. Collagen cross-linking defect: Impairs lysyl oxidase → weak fibrous cap → plaque rupture risk.
  6. Methylation disruption: SAM depletion → hypomethylation of DNA, altered gene expression.
  7. Inflammation: ↑MCP-1, IL-6, CRP → monocyte recruitment, plaque instability.

Clinical Implications

  • Associated with MI, stroke, DVT/PE, heart failure, PAD.
  • Folic acid (0.8–1 mg), B12 (500 µg), B6 (10–25 mg) lower levels but RCT outcomes mixed (HOPE-2, NORVIT).
  • Screening: Consider in premature CVD, family history, renal disease.

Homocysteine is a marker of disrupted one-carbon metabolism; treatment targets underlying nutritional/renal/genetic causes.

Cardiovascular Disease - Related Articles